Phaseline

Companies › Oncomatryx Biopharma

Oncomatryx Biopharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OMTX705
anti-FAP antibody-drug conjugate
FAPPhase 1Advanced Solid Tumor; Pancreatic Adenocarcinoma MetastaticDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05547321OMTX705Phase 1Advanced Solid TumorOncologyDec 2027
NCT07377045OMTX705Phase 1Pancreatic Adenocarcinoma MetastaticOncologyMar 2029

Targets

FAP (1)

Companies with the same targets

Chengdu New Radiomedicine Technology Avacta Life Sciences Blue Earth Diagnostics Novartis Ratio Therapeutics Beijing Biotech SOFIE Philogen BioInvent International Lantheus Medical Imaging

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.